Salvador Espino y Sosa

Dr. Salvador Espino y Sosa

Instituto Nacional de Perinatología, Mexico City, Ciudad de México, Mexico
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Johnatan TorresJohnatan Torres
Johnatan Torres
Salvador Espino y SosaSalvador Espino y Sosa
Salvador Espino y Sosa
Raigam Jafet Martinez Martinez-PortillaRaigam Jafet Martinez Martinez-Portilla
Raigam Jafet Martinez Martinez-Portilla
HBHector Borboa-Olivares
Hector Borboa-Olivares
GEGuadalupe Estrada-Gutierrez
Guadalupe Estrada-Gutierrez
LRLOURDES ROJAS
LOURDES ROJAS
Preeclampsia (PE) is a multifactorial pregnancy disorder characterized by hypertension and proteinuria, posing significant risks to both maternal and fetal health. Despite extensive research, its complex pathophysiology remains incompletely understood. This narrative review aims to elucidate the intricate mechanisms contributing to PE, focusing on abnormal placentation, maternal systemic response, oxidative stress, inflammation, and genetic and epigenetic factors. This review synthesizes findings from recent studies, clinical trials, and meta-analyses, highlighting key molecular and cellular pathways involved in PE. The review integrates data on oxidative stress biomarkers, angiogenic factors, immune interactions, and mitochondrial dysfunction. PE is initiated by poor placentation due to inadequate trophoblast invasion and improper spiral artery remodeling, leading to placental hypoxia. This triggers the release of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sEng), causing widespread endothelial dysfunction and systemic inflammation. Oxidative stress, mitochondrial abnormalities, and immune dysregulation further exacerbate the condition. Genetic and epigenetic modifications, including polymorphisms in the Fms-like tyrosine kinase 1 (FLT1) gene and altered microRNA (miRNA) expression, play critical roles. Emerging therapeutic strategies targeting oxidative stress, inflammation, angiogenesis, and specific molecular pathways like the heme oxygenase-1/carbon monoxide (HO-1/CO) and cystathionine gamma-lyase/hydrogen sulfide (CSE/H2S) pathways show promise in mitigating preeclampsia’s effects. PE is a complex disorder with multifactorial origins involving abnormal placentation, endothelial dysfunction, systemic inflammation, and oxidative stress. Despite advances in understanding its pathophysiology, effective prevention and treatment strategies remain limited. Continued research is essential to develop targeted therapies that can improve outcomes for both mothers and their babies.

1 February 2021 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
Raigam Jafet Martinez Martinez-PortillaRaigam Jafet Martinez Martinez-Portilla
Raigam Jafet Martinez Martinez-Portilla
ASAlexandros Sotiriadis
Alexandros Sotiriadis
CCChristos Chatzakis
Christos Chatzakis
Johnatan TorresJohnatan Torres
Johnatan Torres
Salvador Espino y SosaSalvador Espino y Sosa
Salvador Espino y Sosa
LPLiona C. Poon
Liona C. Poon
Objective: There are limited, unmatched data reporting low complication rates in pregnant women with coronavirus disease 2019 (COVID‐19). The aim of this study was to compare COVID‐19‐related outcomes between pregnant and non‐pregnant women after adjusting for potential risk factors for severe outcomes. Methods: Data were obtained from the COVID‐19 National Data Registry of Mexico, which is an ongoing prospective cohort of people of any age with clinically suspected severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and admitted to 475 monitoring hospitals. This study included pregnant and non‐pregnant women of reproductive age (15–45 years) with COVID‐19 confirmed by reverse transcription polymerase chain reaction. To adjust for underlying risk factors, propensity score matching was conducted for chronic obstructive pulmonary disease, asthma, smoking, hypertension, cardiovascular disease, obesity, diabetes, chronic renal disease, immunosuppression, age, language, nationality and level of health insurance. The primary outcome was death. Secondary outcomes were pneumonia, intubation and intensive care unit (ICU) admission. Results: The cohort comprised 5183 pregnant and 175 905 non‐pregnant women with COVID‐19. The crude (unmatched) rates of death, pneumonia, intubation and ICU admission in pregnant compared with non‐pregnant women were 1.5% vs 1.5%, 9.9% vs 6.5%, 8.1% vs 9.9% and 13.0% vs 6.9%, respectively. After propensity score matching (5183 pregnant and 5183 non‐pregnant matched women), pregnant women had a higher odds of death (odds ratio (OR), 1.84; 95% CI, 1.26–2.69), pneumonia (OR, 1.86; 95% CI, 1.60–2.16) and ICU admission (OR, 1.86; 95% CI, 1.41–2.45) than non‐pregnant women, but similar odds of intubation (OR, 0.93; 95% CI, 0.70–1.25). Conclusion: After adjusting for background demographic and medical factors, pregnancy is a risk factor for death, pneumonia and ICU admission in SARS‐CoV‐2‐infected women of reproductive age. Copyright © 2020 ISUOG. Published by John Wiley & Sons Ltd.

Verified
Journal Article
Open access
PDF file
Salvador Espino y SosaSalvador Espino y Sosa
Salvador Espino y Sosa
Arturo Flores-PliegoArturo Flores-Pliego
Arturo Flores-Pliego
Aurora Espejel-NuñezAurora Espejel-Nuñez
Aurora Espejel-Nuñez
DMDiana Medina-Bastidas
Diana Medina-Bastidas
FVFelipe Vadillo-Ortega
Felipe Vadillo-Ortega
GEGuadalupe Estrada-Gutierrez
Guadalupe Estrada-Gutierrez
Preeclampsia is a severe pregnancy complication globally, characterized by poor placentation triggering vascular dysfunction. Matrix metalloproteinases (MMPs) exhibit proteolytic activity implicated in the efficiency of trophoblast invasion to the uterine wall, and a dysregulation of these enzymes has been linked to preeclampsia. A decrease in MMP-2 and MMP-9 interferes with the normal remodeling of spiral arteries at early pregnancy stages, leading to the initial pathophysiological changes observed in preeclampsia. Later in pregnancy, an elevation in MMP-2 and MMP-9 induces abnormal release of vasoactive factors conditioning hypertension. Although these two enzymes lead the scene, other MMPs like MMP-1 and MMP-14 seem to have a role in this pathology. This review gathers published recent evidence about the implications of different MMPs in preeclampsia, and the potential use of these enzymes as emergent biomarkers and biological therapeutic targets, focusing on studies involving human subjects.

BSBlanca Vianey Suarez-Rico
Blanca Vianey Suarez-Rico
GEGuadalupe Estrada-Gutierrez
Guadalupe Estrada-Gutierrez
MSMaribel Sánchez-Martínez
Maribel Sánchez-Martínez
OPOtilia Perichart
Otilia Perichart
CRCarolina Rodríguez-Hernández
Carolina Rodríguez-Hernández
EREnrique Reyes-Muñoz
Enrique Reyes-Muñoz
The COVID-19 lockdown represents a new challenge for mental health researchers and clinical practitioners. This cross-sectional study aimed to investigate the prevalence of depression, anxiety, and perceived stress in postpartum Mexican women. The study included 293, 4–12-week postpartum women over the age of 18. The Edinburgh Postpartum Depression Scale (EPDS), Trait-State Trait Anxiety Inventory (T-STAI), and Ten Perceived Stress Scale (PSS-10), which are all questionnaires validated for the Mexican population, were applied using a web-based online survey. Prevalence and 95% confidence intervals (CIs) were calculated. The mean ± standard deviation (SD) of the maternal age was 29.9 ± 6.3 years; the EPDS score: 11 ± 6, T-STAI score: 41.7 ± 12.3, and PSS-10 score: 17.1 ± 7. The prevalence (95% CI) of the postpartum depression symptoms was 39.2% (34–45%), trait anxiety symptoms were found among 46.1% (32–43%) of the participants, and moderate and high perceived stress were in 58% (52–64) and 10.9% (7.8–15) of the participants, respectively. The prevalence of depressive symptoms, generalized anxiety, and perceived stress was higher among postpartum Mexican women during the COVID-19 outbreak than before the lockdown. Our findings highlight the importance of monitoring perinatal mental health during pandemics and the need to design effective psychologic interventions for these patients.

Verified
Journal Article
Open access
PDF file
Johnatan TorresJohnatan Torres
Johnatan Torres
IMIrma Eloisa Monroy Muñoz
Irma Eloisa Monroy Muñoz
JPJavier Pérez-Durán
Javier Pérez-Durán
Juan Mario Solis ParedesJuan Mario Solis Paredes
Juan Mario Solis Paredes
Zaira Alexi Camacho-Martinez Camacho-MartinezZaira Alexi Camacho-Martinez Camacho-Martinez
Zaira Alexi Camacho-Martinez Camacho-Martinez
EREnrique Reyes-Muñoz
Enrique Reyes-Muñoz
Gestational diabetes (GD) is a metabolic disorder characterized by glucose intolerance during pregnancy, significantly impacting maternal and fetal health. Its global prevalence is approximately 14%, with risk factors including obesity, family history of diabetes, advanced maternal age, and ethnicity, which are linked to cellular and molecular disruptions in glucose regulation and insulin resistance. GD is associated with short- and long-term complications for both the mother and the newborn. For mothers, GD increases the risk of developing type 2 diabetes, cardiovascular diseases, and metabolic syndrome. In the offspring, exposure to GD in utero predisposes them to obesity, glucose intolerance, and metabolic disorders later in life. This review aims to elucidate the complex cellular and molecular mechanisms underlying GD to inform the development of effective therapeutic strategies. A systematic review was conducted using medical subject headings (MeSH) terms related to GD’s cellular and molecular pathophysiology. Inclusion criteria encompassed original studies, systematic reviews, and meta-analyses focusing on GD’s impact on maternal and fetal health, adhering to PRISMA guidelines. Data extraction captured study characteristics, maternal and fetal outcomes, key findings, and conclusions. GD disrupts insulin signaling pathways, leading to impaired glucose uptake and insulin resistance. Mitochondrial dysfunction reduces ATP production and increases reactive oxygen species, exacerbating oxidative stress. Hormonal influences, chronic inflammation, and dysregulation of the mammalian target of rapamycin (mTOR) pathway further impair insulin signaling. Gut microbiota alterations, gene expression, and epigenetic modifications play significant roles in GD. Ferroptosis and placental dysfunction primarily contribute to intrauterine growth restriction. Conversely, fetal macrosomia arises from maternal hyperglycemia and subsequent fetal hyperinsulinemia, resulting in excessive fetal growth. The chronic inflammatory state and oxidative stress associated with GD exacerbate these complications, creating a hostile intrauterine environment. GD’s complex pathophysiology involves multiple disruptions in insulin signaling, mitochondrial function, inflammation, and oxidative stress. Effective management requires early detection, preventive strategies, and international collaboration to standardize care and improve outcomes for mothers and babies.

27 July 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OPOtilia Perichart
Otilia Perichart
CMCinthya Muñoz-Manrique
Cinthya Muñoz-Manrique
ARAngélica Reyes-López
Angélica Reyes-López
MTMaricruz Tolentino-Dolores
Maricruz Tolentino-Dolores
Salvador Espino y SosaSalvador Espino y Sosa
Salvador Espino y Sosa
MRMa Cristina Ramírez-González
Ma Cristina Ramírez-González
Obesity during pregnancy increases the risk of adverse clinical outcomes and is associated with low-grade chronic inflammation. We describe maternal metabolic risk and inflammation by maternal weight status, and evaluate the association of metabolic and inflammatory markers with birthweight in a group of pregnant Mexican women. This study derived from a prospective cohort of healthy pregnant women <14 weeks of gestation, receiving prenatal care at National Institute of Perinatology (Mexico, 2009–2013). Metabolic and inflammatory markers were measured in maternal serum in all three pregnancy trimesters (1st: 11.42±1.7; 2nd: 21.06±2.4; 3rd: 32.74±2.3 weeks). Pregestational weight was self-reported, and body mass index (BMI) was calculated. Gestational weight gain was evaluated in the third trimester. Newborn´s weight was measured at birth. We carried out correlations, general mixed linear model and regression analyses, based on pregestational weight (self-reported), body mass index (BMI), gestational weight gain (evaluated in the third trimester) and newborn weight (measured at birth). Of the 177 women included in the study (mean age = 26.93±8.49), thirty-eight percent (n = 67) were overweight or had obesity, and 32.8% (n = 58) showed excessive gestational weight gain. We found insulin, lipids (including total cholesterol, LDL-cholesterol, HDL-cholesterol, and triglycerides-TG), leptin and interleukin 1b (IL-1b) all increased significantly (p<0.05) during pregnancy. Pregestational maternal weight status altered longitudinal concentrations of insulin, leptin, adiponectin, TG and C reactive protein. Excessive gestational weight gain was associated with higher maternal insulin in the third trimester (p<0.05). Early pregnancy leptin and TNFα were determinants of birthweight in women with normal weight, but not in overweight or obese women. Maternal weight status affected the concentrations of insulin, leptin, adiponectin, triglycerides and C reactive protein throughout pregnancy. The role of early leptin and TNFα in fetal growth need further study given the association was only observed in normal weight women. This study presents data distribution of metabolic and inflammatory markers of normal weight and overweight/obese women that did not develop GDM, preeclampsia nor macrosomia.